Transasia Bags Best Medical Devices – IVD Company Excellence Awards 2019

IMT News Desk
IMT News Desk
· 2 min read
transasia
Mrs. & Mr. Vazirani receiving the award on behalf of Transasia

Transasia Bio-Medicals Ltd., India’s Leading IVD Company, today announced that it has been adjudged the ‘Best Company in Medical Devices’at Excellence Awards 2019.

Transasia was selected the winner, from among other leading names in the industry,and the award is a recognition given to companies with outstanding services and contribution to the healthcare sector. This is the second consecutive year that Transasia has been receiving the award in the same category. The award was presented at a grand ceremony on 22nd February, 2019 and attended by some of the most well-known names of the industry.

On receiving the award, Suresh Vazirani, Chairman & Managing Director, Transasia, said “I am thankful to the jury members for recognizing Transasia as the Best Medical Device Company for the second year in a row. We are doubly delighted as this prestigious award comes our way, as we celebrate our 40th anniversary. For the last four decades, Transasia has been committed to offering laboratory testing instruments of the highest quality to meet the needs of the country for affordable diagnostics. We pride ourselves in offering the strongest service network in the country, from the largest city to the smallest town. We are thankful to the medical fraternity who trust us in offering their patients early and accurate diagnosis.”

The award ceremony was preceded by the a healthcare conference held at Pragati Maidan in New Delhi.

During the panel discussion on ‘Affordable Access to Medical Devices’, Mrs. Mala Vazirani, Executive Director, Transasia Bio-Medicals Ltd. highlighted the impact of technology on healthcare. “Technological innovation is critical to expanding the reach of medical services, lowering costs of deployment and improving patient outcomes,” she said.

Transasia has been meeting India’s needs for essential diagnosis through affordable and innovative, Made in India products and solutions. Today, it boasts of over 65,000 installations in 35,000 labs across India and reaching out to millions in more than 100 countries worldwide. Through its R&D centres in India and abroad, Transasia has developed world-class technology for a wide range of products and solutions in Clinical Chemistry, Hematology, Immunology, Diabetes Management, Urinalysis, Coagulation, Critical Care and Microbiology.

 

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk